Properties of TAN-67, a nonpeptide δ-opioid receptor agonist, at cloned human δ-and μ-opioid receptors

1995 ◽  
Vol 291 (2) ◽  
pp. 129-134 ◽  
Author(s):  
Richard J. Knapp ◽  
Robert Landsman ◽  
Sue Waite ◽  
Ewa Malatynska ◽  
Eva Varga ◽  
...  
2012 ◽  
Vol 3 (7) ◽  
pp. 505-509 ◽  
Author(s):  
Matthew D. Metcalf ◽  
Ajay S. Yekkirala ◽  
Michael D. Powers ◽  
Kelley F. Kitto ◽  
Carolyn A. Fairbanks ◽  
...  

1995 ◽  
Vol 275 (1) ◽  
pp. 105-108 ◽  
Author(s):  
Xiao-Hong Chen ◽  
Jill U. Adams ◽  
Ellen B. Geller ◽  
J.Kim DeRiel ◽  
Martin W. Adler ◽  
...  

1985 ◽  
Vol 68 (2) ◽  
pp. 209-213 ◽  
Author(s):  
Fabrizio Pasanisi ◽  
Lesley Sloan ◽  
Peter C. Rubin

1. Opioid receptors exist in at least three forms: μ, δ and κ. Agonists at μ receptors produce orthostatic hypotension in man by a mechanism involving a reduction in baroreflex sensitivity. We describe here the cardiovascular properties of metkephamid, a relatively selective δ opioid receptor agonist. 2. Blood pressure, heart rate and plasma noradrenaline concentration were measured over a 7 h period in eight normal young male volunteers in the supine position and after 70° 5 min head-up tilt, after receiving metkephamid (50 mg intramuscularly) or placebo. 3. Metkephamid increased heart rate in the supine position with no change in blood pressure or plasma noradrenaline concentration. This was accompanied by symptoms consistent with an anti-muscarinic anticholinergic effect. 4. Head-up tilt resulted in substantial hypotension after metkephamid with an attenuated change in heart rate and no increase in noradrenaline concentration. 5. We conclude that δ as well as μ opioid receptor agonists can produce orthostatic hypotension with attenuation of heart rate response. Metkephamid possesses anticholinergic properties not seen with μ receptor agonists, suggesting a possible role of δ opioid receptors in cholinergic activity.


2020 ◽  
Vol 237 (12) ◽  
pp. 3591-3602
Author(s):  
Sanjana Mada ◽  
Lisa R. Gerak ◽  
Amélie Soyer ◽  
David R. Maguire ◽  
Zehua Hu ◽  
...  

1998 ◽  
Vol 274 (3) ◽  
pp. H909-H914 ◽  
Author(s):  
Jo El J. Schultz ◽  
Anna K. Hsu ◽  
Hiroshi Nagase ◽  
Garrett J. Gross

We have previously shown that delta (δ)-opioid receptors, most notably δ1, are involved in the cardioprotective effect of ischemic preconditioning (PC) in rats; however, the mechanism by which δ-opioid receptor-induced cardioprotection is mediated remains unknown. Therefore, we hypothesized that several of the known mediators of ischemic PC such as the ATP-sensitive potassium (KATP) channel and Gi/oproteins are involved in the cardioprotective effect produced by δ1-opioid receptor activation. To address these possibilities, anesthetized, open-chest Wistar rats were randomly assigned to five groups. Control animals were subjected to 30 min of coronary artery occlusion and 2 h of reperfusion. To demonstrate that stimulating δ1-opioid receptors produces cardioprotection, TAN-67, a new selective δ1-agonist, was infused for 15 min before the long occlusion and reperfusion periods. In addition, one group received 7-benzylidenenaltrexone (BNTX), a selective δ1-antagonist, before TAN-67. To study the involvement of KATPchannels or Gi/oproteins in δ1-opioid receptor-induced cardioprotection, glibenclamide (Glib), a KATPchannel antagonist, or pertussis toxin (PTX), an inhibitor of Gi/oproteins, was administered before TAN-67. Infarct size (IS) as a percentage of the area at risk (IS/AAR) was determined by tetrazolium stain. TAN-67 significantly reduced IS/AAR as compared with control (56 ± 2 to 27 ± 5%, n = 5, P < 0.05). The cardioprotective effect of TAN-67 was completely abolished by BNTX, Glib, and PTX (51 ± 3, 53 ± 5, and 61 ± 4%, n = 6 for each group, respectively). These results are the first to suggest that stimulating the δ1-opioid receptor elicits a cardioprotective effect that is mediated via Gi/oproteins and KATPchannels in the intact rat heart.


Sign in / Sign up

Export Citation Format

Share Document